• Blog
  • California Consumer Privacy Act (CCPA)
  • Cart
  • Checkout
  • Contact
  • DMCA
  • Home
  • My account
  • Privacy Policy
  • Shop
Tuesday, October 28, 2025
  • Login
Buyer's Insight
  • Home
  • Top Stories
  • Local News
    • Politics
    • Business & Economy
    • Entertainment
    • Sports
  • Health
  • Lifestyle
  • Science & Environment
  • Technology
  • Review Radar
    • Weight Loss Products Reviews
    • Forex Trading
    • Shop
  • Contact
No Result
View All Result
  • Home
  • Top Stories
  • Local News
    • Politics
    • Business & Economy
    • Entertainment
    • Sports
  • Health
  • Lifestyle
  • Science & Environment
  • Technology
  • Review Radar
    • Weight Loss Products Reviews
    • Forex Trading
    • Shop
  • Contact
No Result
View All Result
Buyer's Insight
No Result
View All Result

Biocon Arm receives the temporary approval of the USFDA for the tablets used to treat stomach aches

Michael Johnson by Michael Johnson
October 7, 2025
in Business & Economy
Reading Time: 1 min read
0
0
SHARES
0
VIEWS
Biocon Ltd. actions Attend volatile movements on Tuesday, October 7, after its entirely subsidiary belonging to provisional approval of the Food and Drug Administration of the United States (USFDA) for the new abbreviated medication request (ANDA) for the Rifaximin tablets, 550 mg.

Biocon Pharma Ltd., Biocon’s Arm, has teamed up with Carnegie Pharmaceuticals for the drug.

Tablets are a rifamycin antibacterial indicated to reduce the risk of manifest hepatic epippleathy and to treat irritable colon syndrome with adults, according to Biocon.

In an earlier interaction with CNBC-TV18, biocon management stressed that it is well placed to stimulate the creation of long-term value during exercise 26 and beyond, with strong progress in all its companies and an increased capacity of American acquisitions by generic Syngene and Biocon.

Biocon shares had opened more on Tuesday, but are currently in the event of the summits, exchanging 0.3% more to $ 348.65. The action decreased by 4% in the last month and is down more than 5% on an annual basis.

Source link

Post Views: 0
Tags: achesapprovalArmBioconreceivesstomachTabletstemporarytreatUSFDA
Previous Post

Do buyers care who designs fashion collections?

Next Post

Techcrunch Disrupt 2025 The exhibition tables are sold quickly and time is exhausted

Related Posts

Business & Economy

Federal health insurance premiums will see another significant increase in 2026

October 10, 2025
Business & Economy

ONGC to provide first guarantee in 15 years for unit bond sale, says report

October 10, 2025
Business & Economy

US opens investigation into Tesla after new accidents involving its self-driving technology

October 9, 2025
Business & Economy

Levi Strauss (LEVI) Third Quarter 2025 Results

October 9, 2025
Business & Economy

Trump Administration Sends Student Loan Cancellation Notices

October 9, 2025
Business & Economy

Asia Economic Calendar October 10, 2025 – RBA’s Bullock and Fed’s Daly speak

October 9, 2025
Next Post

Techcrunch Disrupt 2025 The exhibition tables are sold quickly and time is exhausted

Zoma News Pulse

  • Home
  • California Consumer Privacy Act (CCPA)
  • Contact
  • DMCA
  • Privacy Policy

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Top Stories
  • Local News
    • Politics
    • Business & Economy
    • Entertainment
    • Sports
  • Health
  • Lifestyle
  • Science & Environment
  • Technology
  • Review Radar
    • Weight Loss Products Reviews
    • Forex Trading
    • Shop
  • Contact